Table 4.
Tracer(s) | Patient number |
Disease stage | Study objective |
Sensitivity | Specificity | Year | Group |
---|---|---|---|---|---|---|---|
11C-methionine, 18F-FDG | 10 | Advanced | Staging | NA | NA | 1999 | Mascapinlac HA, et al |
11C-methionine, 18F-FDG | 12 | Advanced | Staging | 72% (48%) | NA | 2002 | Nunez R, et al. |
11C-methionine | 20 | Early | Staging | 35% | 47% | 2005 | Tooth G, et al |
18F-FACBC | 15 | Advanced | Staging, restaging |
NA | NA | 2007 | Schuster DM, et al. |
18F-FDHT, 18F-FDG | 7 | Advanced | Staging | 78% (97%) | NA | 2004 | Larson SM, et al. |
18F-FDHT | 20 | Advanced | Staging | 63% | NA | 2005 | Dehdasthi F, et al. |
18F-fluoride | 44 | Bone metastases | Staging | 100% | 100% | 2006 | Even-Sapir E, et al |
18F-fluoride, 18F-FCH | 38 | Bone metastases | Staging | 81% (74%) | 93% (99%) | 2008 | Beheshti M, et al |